JP2013537426A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537426A5
JP2013537426A5 JP2013524945A JP2013524945A JP2013537426A5 JP 2013537426 A5 JP2013537426 A5 JP 2013537426A5 JP 2013524945 A JP2013524945 A JP 2013524945A JP 2013524945 A JP2013524945 A JP 2013524945A JP 2013537426 A5 JP2013537426 A5 JP 2013537426A5
Authority
JP
Japan
Prior art keywords
adenovirus
cancer
item
orf3
impaired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013524945A
Other languages
English (en)
Japanese (ja)
Other versions
JP5905460B2 (ja
JP2013537426A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/048005 external-priority patent/WO2012024350A2/en
Publication of JP2013537426A publication Critical patent/JP2013537426A/ja
Publication of JP2013537426A5 publication Critical patent/JP2013537426A5/ja
Application granted granted Critical
Publication of JP5905460B2 publication Critical patent/JP5905460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013524945A 2010-08-16 2011-08-16 抗がんアデノウイルス Active JP5905460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37421510P 2010-08-16 2010-08-16
US61/374,215 2010-08-16
PCT/US2011/048005 WO2012024350A2 (en) 2010-08-16 2011-08-16 Anti-cancer adenoviruses

Publications (3)

Publication Number Publication Date
JP2013537426A JP2013537426A (ja) 2013-10-03
JP2013537426A5 true JP2013537426A5 (OSRAM) 2014-09-18
JP5905460B2 JP5905460B2 (ja) 2016-04-20

Family

ID=45605646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524945A Active JP5905460B2 (ja) 2010-08-16 2011-08-16 抗がんアデノウイルス

Country Status (10)

Country Link
US (1) US9187733B2 (OSRAM)
EP (1) EP2606137B1 (OSRAM)
JP (1) JP5905460B2 (OSRAM)
KR (1) KR101667094B1 (OSRAM)
CN (1) CN103180448B (OSRAM)
AU (1) AU2011292119B2 (OSRAM)
BR (1) BR112013003579A2 (OSRAM)
CA (1) CA2807778C (OSRAM)
SG (1) SG187785A1 (OSRAM)
WO (1) WO2012024350A2 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024350A2 (en) * 2010-08-16 2012-02-23 Salk Institute For Biological Studies Anti-cancer adenoviruses
CN110592123A (zh) * 2012-03-13 2019-12-20 萨克生物研究学院 使用腺病毒和化学二聚体的选择性细胞寻靶
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
AU2016333996B2 (en) 2015-10-05 2020-05-28 Salk Institute For Biological Studies Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
AU2020282369A1 (en) 2019-05-30 2022-01-20 Seattle Project Corp. Modified adenoviruses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA137094A (en) 1911-08-31 1911-11-28 Sheppe, Alice L. Cloth measuring and price calculating machine
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
DE69903229T2 (de) * 1998-07-07 2003-06-26 Transgene S.A., Strasburg/Strasbourg Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression
EP1083229A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
US7445929B2 (en) * 2000-05-26 2008-11-04 Dainippon Sumitomo Pharma Co., Ltd. Recombinant adenovirus vector having a reduced side effect
US20020106382A1 (en) * 2000-07-14 2002-08-08 Young Charles S.H. Modified adenovirus and uses thereof
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
EP1545627A4 (en) 2002-10-01 2006-12-27 Univ Duke TARGETED TUMOR THERAPY THROUGH THE USE OF RECOMBINANT ADENOVIRUS VECTORS FOR SELECTIVE REPLICATION IN HYPOXIC TUMOR REGIONS
US20050201978A1 (en) 2003-11-17 2005-09-15 Lipton James S. Tumor and infectious disease therapeutic compositions
JP2012504140A (ja) * 2008-09-26 2012-02-16 オーバーン・ユニバーシティ 非複製性ベクターワクチンの粘膜投与による鳥類の免疫処置
WO2012024350A2 (en) * 2010-08-16 2012-02-23 Salk Institute For Biological Studies Anti-cancer adenoviruses

Similar Documents

Publication Publication Date Title
JP2013537426A5 (OSRAM)
Barkauskas et al. Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
MY183703A (en) Oncolytic adenovirus encoding a b7 protein
MX2024005757A (es) Virus pichinde de tres segmentos como vectores de vacunas.
RU2016123086A (ru) Способы и композиции для лечения болезни хантингтона
WO2012142529A3 (en) Clonal strains of attenuated vaccinia viruses and methods of use thereof
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
FR2981643B1 (fr) Procede de preparation d'un materiau composite silicium/carbone, materiau ainsi prepare, et electrode notamment electrode negative, comprenant ce materiau.
JP2013530155A5 (OSRAM)
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
BR112014019049A2 (pt) adenovirus imunogênico
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
IN2015DN00376A (OSRAM)
JP2018512047A5 (OSRAM)
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
JP2011157399A5 (OSRAM)
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
BR112014028315A2 (pt) mposto, métodos para introdução de uma molécula dentro do citosol de uma célula, para obter a morte de uma célula, para expressar uma molécula antigênica ou uma parte da mesma na superfície de uma célula, e para tratamento ou prevenção de uma doença, distúrbio ou infecção em um paciente, composição farmacêutica, célula ou uma população de células, e, kit
NZ628385A (en) Batches of recombinant adenovirus with altered terminal ends
JP2017532343A5 (OSRAM)
MA39096B1 (fr) Anticorps spécifiques à fcrn
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
JP2018512597A5 (OSRAM)
MD4481B1 (ro) Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV